Umut Erhan, Denmark
Novo Nordisk A/S Global Medical Affairs, Semaglutide Once WeeklyPresenter of 1 Presentation
USE OF A MOBILE HEALTH APPLICATION TO SUPPORT INITIATION OF ONCE-WEEKLY SEMAGLUTIDE: AN ANALYSIS FROM 13 COUNTRIES OF USER ENGAGEMENT DURING THE DOSE ESCALATION PERIOD
Abstract
Background and Aims
Successful management of patients with T2D relies on successful treatment initiation and adherence. A mobile health (mHealth) app that includes planning, body weight and dose tracking features has been developed to support patients during the initiation (first 12 weeks) of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist approved for type 2 diabetes. Here, we provide an overview of users’ interaction with the app since its launch in August 2018.
Methods
Data were analysed both overall and separately for active (≤3 consecutive weeks without interacting with [opening] the app) and less active (>3 consecutive weeks without interacting with the app) users.
Results
Of 7,789 registered users, 2,820 were active and 4,969 were less active. ‘How to’ resources were frequently viewed during the first week by both user groups. Resources most viewed were ‘when to take’ and ‘side effects’. Overall, 73.1% registered users set up injection reminders during the first week and 39.8% set up anchoring plans (where the user anchors injection behaviour to an existing habit in their routine). Setting up anchoring plans resulted in more consistent self-recorded injection rates throughout the 12-week dose escalation period in active (+7%) and less active (+20%) users vs users not setting up plans; both p<0.05 (Figure)
Conclusions
This analysis suggests that use of the mHealth app and setting up anchoring plans is associated with more consistent use of treatment as assessed by self-recorded injection rates, regardless of overall engagement levels. This highlights the benefits of medication-specific mHealth apps as patient support tools when initiating new medications.
